Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment

Abstract The alteration of DNA methylation patterns are a key component of disease onset and/or progression. Our objective was to evaluate the differences in Long Interspersed Nuclear Element-1 (LINE-1) methylation levels, as a surrogate marker of global DNA methylation, between multiple sclerosis (...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	María Jesús Pinto-Medel, Begoña Oliver-Martos, Patricia Urbaneja-Romero, Isaac Hurtado-Guerrero, Jesús Ortega-Pinazo, Pedro Serrano-Castro, Óscar Fernández, Laura Leyva
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1edab2bd9433428da57286da0b23a397
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1edab2bd9433428da57286da0b23a397
record_format	dspace
spelling	oai:doaj.org-article:1edab2bd9433428da57286da0b23a3972021-12-02T15:05:56ZGlobal methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment10.1038/s41598-017-09301-22045-2322https://doaj.org/article/1edab2bd9433428da57286da0b23a3972017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-09301-2https://doaj.org/toc/2045-2322Abstract The alteration of DNA methylation patterns are a key component of disease onset and/or progression. Our objective was to evaluate the differences in Long Interspersed Nuclear Element-1 (LINE-1) methylation levels, as a surrogate marker of global DNA methylation, between multiple sclerosis (MS) patients and healthy controls. In addition, we assessed the association of LINE-1 methylation with clinical disease activity in patients treated with IFNbeta (IFNβ). We found that individuals with high levels of LINE-1 methylation showed 6-fold increased risk of suffering MS. Additionally, treated MS patients who bear high LINE-1 methylation levels had an 11-fold increased risk of clinical activity. Moreover, a negative correlation between treatment duration and percentage of LINE-1 methylation, that was statistically significant exclusively in the group of patients without clinical activity, was observed. Our data suggest that in MS patients, a slight global DNA hypermethylation occurs that may be related to the pathophysiology of the disease. In addition, global DNA methylation levels could play a role as a biomarker for the differential clinical response to IFNβ.María Jesús Pinto-MedelBegoña Oliver-MartosPatricia Urbaneja-RomeroIsaac Hurtado-GuerreroJesús Ortega-PinazoPedro Serrano-CastroÓscar FernándezLaura LeyvaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q María Jesús Pinto-Medel Begoña Oliver-Martos Patricia Urbaneja-Romero Isaac Hurtado-Guerrero Jesús Ortega-Pinazo Pedro Serrano-Castro Óscar Fernández Laura Leyva Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
description	Abstract The alteration of DNA methylation patterns are a key component of disease onset and/or progression. Our objective was to evaluate the differences in Long Interspersed Nuclear Element-1 (LINE-1) methylation levels, as a surrogate marker of global DNA methylation, between multiple sclerosis (MS) patients and healthy controls. In addition, we assessed the association of LINE-1 methylation with clinical disease activity in patients treated with IFNbeta (IFNβ). We found that individuals with high levels of LINE-1 methylation showed 6-fold increased risk of suffering MS. Additionally, treated MS patients who bear high LINE-1 methylation levels had an 11-fold increased risk of clinical activity. Moreover, a negative correlation between treatment duration and percentage of LINE-1 methylation, that was statistically significant exclusively in the group of patients without clinical activity, was observed. Our data suggest that in MS patients, a slight global DNA hypermethylation occurs that may be related to the pathophysiology of the disease. In addition, global DNA methylation levels could play a role as a biomarker for the differential clinical response to IFNβ.
format	article
author	María Jesús Pinto-Medel Begoña Oliver-Martos Patricia Urbaneja-Romero Isaac Hurtado-Guerrero Jesús Ortega-Pinazo Pedro Serrano-Castro Óscar Fernández Laura Leyva
author_facet	María Jesús Pinto-Medel Begoña Oliver-Martos Patricia Urbaneja-Romero Isaac Hurtado-Guerrero Jesús Ortega-Pinazo Pedro Serrano-Castro Óscar Fernández Laura Leyva
author_sort	María Jesús Pinto-Medel
title	Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
title_short	Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
title_full	Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
title_fullStr	Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
title_full_unstemmed	Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
title_sort	global methylation correlates with clinical status in multiple sclerosis patients in the first year of ifnbeta treatment
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/1edab2bd9433428da57286da0b23a397
work_keys_str_mv	AT mariajesuspintomedel globalmethylationcorrelateswithclinicalstatusinmultiplesclerosispatientsinthefirstyearofifnbetatreatment AT begonaolivermartos globalmethylationcorrelateswithclinicalstatusinmultiplesclerosispatientsinthefirstyearofifnbetatreatment AT patriciaurbanejaromero globalmethylationcorrelateswithclinicalstatusinmultiplesclerosispatientsinthefirstyearofifnbetatreatment AT isaachurtadoguerrero globalmethylationcorrelateswithclinicalstatusinmultiplesclerosispatientsinthefirstyearofifnbetatreatment AT jesusortegapinazo globalmethylationcorrelateswithclinicalstatusinmultiplesclerosispatientsinthefirstyearofifnbetatreatment AT pedroserranocastro globalmethylationcorrelateswithclinicalstatusinmultiplesclerosispatientsinthefirstyearofifnbetatreatment AT oscarfernandez globalmethylationcorrelateswithclinicalstatusinmultiplesclerosispatientsinthefirstyearofifnbetatreatment AT lauraleyva globalmethylationcorrelateswithclinicalstatusinmultiplesclerosispatientsinthefirstyearofifnbetatreatment
_version_	1718388630122135552

Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment

Ejemplares similares